

Public Health Vaccines (PHV) awarded BioMaP-Consortium contract to onshore manufacturing of its PHV01, rVSV-MARV vaccine

PHV to tech transfer production and testing of PHV01 (monovalent VSV ΔG Marburg Angola) to the US to bolster live viral vaccine domestic manufacturing capacity.



CAMBRIDGE, MA, UNITED STATES,
August 6, 2026 /EINPresswire.com/ --

[Public Health Vaccines, LLC](#) (PHV), a biotechnology company out of Cambridge, MA, has been awarded a contract from the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to tech transfer production and testing of its monovalent VSV ΔG Marburg (Angola) vaccine candidate (PHV01) to the United States to bolster live viral vaccine domestic

manufacturing capacity. Domestic capacity for producing live viral vectors—particularly those used in viral hemorrhagic fever vaccines—remains limited, and expanding this capability is essential for strengthening the nation's vaccine manufacturing base, improving health security preparedness, and enabling a faster, more effective response to both known and emerging infectious disease threats.

“

We're proud to partner with BioMaP-Consortium, ATI and ABL on this important program, and we thank BioMaP-Consortium/BARDA for their continued commitment and support.”

*Dr. Joan Fusco, Chief
Operating Officer*

The BioMaP-Consortium brings together pharmaceutical, medical, academic, and scientific organizations working toward successful development and delivery of medical

countermeasure materials and products. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority, under OT number #75A50123D00003.

PHV has been developing PHV01 in collaboration with the BARDA since February of 2019 under

contract #HHSO100201900022C. Since then, the company has successfully advanced the vaccine candidate through Phase 1 clinical testing and will be entering Phase II clinical testing in the coming months. Under this approximately \$11 million award, PHV will transfer the complete PHV01 manufacturing process—including BDS (upstream and downstream) and FDP (formulation, fill/finish)—from offshore facilities to Ascend-ABL's U.S.-based CGMP manufacturing sites in MD and FL. This transfer will establish domestic readiness for Phase 2-scale production and create a foundation for rapid scale-up during emergencies.

PHV's Chief Operating Officer Dr. Joan Fusco stated, "Robust domestic manufacturing capability is essential to a reliable medical countermeasure supply chain for outbreak preparedness and response. This program is a major step toward establishing the U.S.-based capability and capacity needed to produce recombinant VSV-vectored filovirus vaccines. PHV's rVSV-Marburg vaccine leads our vaccine portfolio for filoviruses and reflects our successful technology transfers, established manufacturing processes, and platform expertise. We are proud to partner with BioMaP-Consortium, ATI and ABL on this important program to strengthen U.S. outbreak response readiness, and we thank BioMaP-Consortium/BARDA for their continued commitment and support to advance rVSV-based filovirus vaccines."

Marburg virus is a hemorrhagic fever virus of the Filoviridae family that causes Marburg Virus Disease, a rare but severe hemorrhagic fever that affects people and non-human primates and has a fatality ratio of up to 88%. In addition to being a naturally occurring public health threat, it has been determined to present a material threat to national security by the U.S. Department of Homeland Security. There are currently no licensed vaccines for Marburg virus; PHV01 will help fill this critical unmet medical need. The PHV01 vaccine is leveraging the proven recombinant vesicular stomatitis virus (rVSV) vector platform originally developed by the Public Health Agency of Canada.

About Public Health Vaccines, LLC

Public Health Vaccines, LLC. (PHV), headquartered in Cambridge, Massachusetts, is a privately-held biotechnology company developing products for the prevention and control of emerging infectious diseases. The company's primary focus has been on developing vaccines against viral hemorrhagic fevers utilizing the rVSV platform, including multiple vaccines against filoviruses (Marburg virus, Sudan ebolavirus and Ebola Bundibugyo) and a vaccine against the Paramyxovirus, Nipah virus. PHV funding partners for these programs include the Biomedical Advanced Research and Development Authority (BARDA) for its Marburg vaccine, Sudan ebolavirus vaccine and Ebola Bundibugyo vaccine; and the Coalition for Epidemic Preparedness Innovations (CEPI) for its Nipah vaccine and Ebola Bundibugyo vaccine.

For more information, please visit www.phvaccines.com or email info@phvaccines.com.

Michael S McGinnis
Public Health Vaccines
+1 443-813-4200

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/932046851>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.